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Abstract
Schistosomiasis is a waterborne disease whose life cycle involves freshwater sources
conducive for the survival and reproduction of aquatic snails that form a connective
link between man and water in the life  cycle and transmission of  schistosomiasis.
The African region has network of rivers with freshwater suggesting the presence
of schistosomiasis and difficulty to control. Some communities, due to socioeconomic
challenges,  have  inadequate  sanitation  and  water  supply;  use  of  bush  toilets  for
excretion is commonly practiced. These conditions in Africa also promote transmis-
sion  of  soil-transmitted  helminthiasis.  The  World  Health  Organization  (WHO),  in
response to the public health and socioeconomic impact of neglected tropical diseases,
is  coordinating strategies for the control  and elimination of the diseases including
schistosomiasis and soil-transmitted helminthiasis. As one of the milestones, mapping
of  neglected  tropical  diseases  in  the  African  region  has  been  prioritized  for  the
implementation  of  control  strategies.  In  countries  where  mapping  has  been
completed, WHO and its partners are supplying medicines required for annual mass
treatment for preventive chemotherapy and encourage countries to take ownership
in  implementing  complementary  strategies  for  morbidity  control,  elimination  and
eradication  of  country-specific  neglected  tropical  diseases.  The  mainstay  of
helminthiasis  control  is  preventive chemotherapy,  targeting school  age children to
prevent  morbidity  and  development  of  pathological  manifestations,  including
urogenital  schistosomiasis  that  is  understood  to  contribute  to  HIV  transmission.
Vaccines  are  still  to  be  discovered  and  designed,  with  many  possible  antigen
candidates, but however the immune responses are still to be fully understood. There
is  need  to  understand  the  subtle  link  between  each  component  of  the  immune
responses and the host immunogenetics impacting on the translated immunological
response  of  cytokines  that  are  delicately  controlled  for  cellular  immunity  and
antibody  production.  Currently,  preventive  chemotherapy  treatment  is  the  only
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control method in concert with health education in an attempt to cut the helminthiasis
life cycle.
Keywords: control, schistosomiasis, soil‐transmitted helminthiasis, mass drug admin‐
istration, chemotherapy
1. Introduction
Parasitic worms (helminths) are responsible for chronic infections of over two billion people
worldwide and impose a huge public health burden. The hallmark of helminth infection is
immune modulation of the host's immune response, which both limits immunopathology in
the host while allowing the worms to evade host immune attack. The immune modulation of
host responses during helminth infection has attracted much interest in terms to understand
the generation of protective immunity.  Unfortunately,  the immune modulation occurring
during helminth infection also interferes with the expression of naturally acquired protective
immunity against the parasites, resulting in an accumulation of parasites in the host. Experi‐
mental  Studies  suggest  manipulating  host  regulatory  responses  can  enhance  helminths
vaccine efficacy. In human schistosomiasis, the health impact is not confined to immunopa‐
thology but extends to physical damage resulting from the presence of the parasites and the
passage of parasite eggs as they are excreted from the host via urine or stool. In the case of
urogenital schistosomiasis, infection interferes with child development and health, diminishes
female  reproductive  health  and  increases  susceptibility  to  sexually  transmitted  diseases
including HIV and can lead to bladder cancer.
Currently available control method is treatment of infected people with the antihelminthic
drug praziquantel. Field studies have already demonstrated that praziquantel treatment can
induce protective immunity in chronically infected children, while treatment if conducted
earlier in life would mean children benefit from the effects of praziquantel earlier, thus
avoiding the health costs associated with chronic infections. Praziquantel treatment imparts
on molecular and immune responses, mediating resistance in individuals previously with
chronic schistosome who became resistant against reinfection by the parasites. This concept
of infection‐treatment as immunization is used in some veterinary diseases. There is need to
investigate the transcriptional and post‐translational characteristics underlying resistance to
schistosome. Subsequently, regular childhood treatment may induce protective immune
responses, that is, treatment of primary infections before it becomes chronic, induces regula‐
tory responses that may reduce the efficacy of the effector responses. More studies are required
to understand the activation of regulatory, pro‐ and anti‐inflammatory responses in individ‐
uals who remain susceptible to re‐infection and the mechanisms by which these regulatory
responses modulate effector functions. Such knowledge is important to improving current and
future helminth interventions as well as the development of novel therapeutics against
immune‐mediated pathology arising from parasitic infection or immune dysfunction.
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An important constraint for helminths vaccine development is the paucity of information on
the induction of appropriate effector pathways mediating protective immunity over the
regulatory responses, which modulate them, as well as on mechanisms by which vaccine
efficacy and longevity can be enhanced. Experimental studies of other helminths suggest that
vaccine efficacy can be improved beyond the typical low protection level by neutralizing
immunomodulatory processes. There is missing evidence to identify the key immunomodu‐
lators and their functional mechanisms, which can be manipulated to improve the efficacy of
helminths vaccines and pathways that can be manipulated to enhance the longevity of vaccine‐
induced resistance. In addition, there is currently lack of consensus on markers of vaccine‐
induced protection. However, in the meantime, preventive chemotherapy is the only
alternative in concert with health education.
1.1. Human helminthiasis as neglected tropical diseases
Human helminthiasis are part of the neglected tropical diseases (NTDs), which are a diverse
group of parasitic, viral and bacterial diseases with distinct characteristics, that thrive mainly
among the poorest populations, hinder socioeconomic development and cause substantial
illness for more than one billion people globally [1]. Seventeen NTDs (Figure 1) have been
specified by the World Health Organization (WHO) and these include dengue, buruli ulcer,
cutaneous leishmaniasis, taeniasis/cysticercosis and echinococcosis/hydatidosis, foodborne
trematode infections, soil‐transmitted helminthiasis (STH), intestinal worms, rabies, blinding
trachoma, endemic treponematoses (yaws), leprosy, Chagas disease, Human African trypa‐
nosomiasis, visceral leishmaniasis, dracunculiasis, lymphatic filariasis, onchocerciasis and
schistosomiasis [2]. These NTDs impair physical and intellectual capacities of the affected
persons, thereby perpetuating the cycle of poverty [1]. Forty‐seven countries in the African
region are endemic to at least one NTD and 37 of them (79%) are coendemic for at least five of
these diseases [3].
Figure 1. A list of neglected tropical diseases. Much attention is given to the previously neglected diseases being Ma‐
laria, HIV/AIDS and TB. While schistosomiasis and soil transmitted helminthiasis continue to be neglected. Included
are neglected zoonosis diseases that come about the interactions of humans and their animals.
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Five of the 17 NTDs [lymphatic filariasis, onchocerciasis, schistosomiasis, soil‐transmitted
helminthiasis (STH) and trachoma] are amenable to preventive chemotherapy. Thus,
targeting such disease for control and elimination using available safe medicines and
supported by complementary interventions could provide a noticeable quick win on NTD
for the African region and in particular for the endemic countries. STHs have been specified
as endemic in many countries even though the data collection methods used could be at
variance from those recommended by WHO [3]. Countries in the African region through their
Ministries of Health have not only endorsed the adoption of the resolutions on NTD by the
World Health Assembly (WHA) in 2013, but they also expressed their commitment to scaling
up interventions against the major NTDs [1]. With such an increased momentum to eliminate
NTDs, it is critical that WHO member states implement NTD strategies demonstrating their
commitments.
2. Disease transmission
Schistosomiasis transmission begins most often when people come into contact with bodies of
freshwater in which infected people have urinated or defecated and there is a stage of the life
cycle in intermediate snail host [4]. Transmission is linked to the life cycle of the schistosome
(e.g., egg, miracidium larval form, sporocyst, cercaria, schistosomule, adult schistosome),
when an egg comes in contact with freshwater, where it hatches and releases a miracidium.
The miracidium swims by ciliary movement toward the snail intermediate host and penetrates
its soft tissue. The Schistosoma species are transmitted by different freshwater snails that serve
as intermediate hosts (Figure 2). The miracidium penetrated the snail and develops into
sporocyst that migrates to the hepatic and gonadal tissue of the intermediate snail host. After
2–4 weeks, the sporocysts develop into cercariae [4]. Hundreds of the fork‐tailed cercariae leave
the snail intermediate host under the stimulation of light, swimming in the water until they
find definitive mammalian hosts. The cercariae enters the skin using both mechanical activity
and proteolytic enzymes [5], losing the tail and develops into schistosomules that migrate via
the blood or lymphatic vessels [4]. The schistosomules then migrate to the portal circulation
where they mature into adult worms. Adult S. japonicum, S. mekongi and S. intercalatum worms
stay in the portal and mesenteric vessels, while S. haematobium worms migrate and live in the
vesical plexus. The adult worms mate, with the male adult schistosome embracing the female
worm into its gynaecophoric canal [5]. Four to 6 weeks after the cercaria has penetrated the
human skin, the embraced female adult worm starts producing eggs, except for S. haematobium
worms that take about 60–63 days before oviposition [6]. The adult female worms continue
producing eggs throughout their lifetime, with about half the number of eggs produced are
excreted with feces or urine, while the rest remain trapped in the tissues causing immunopa‐
thology (Figure 2) [7].
2.1. Global public health significance of schistosomiasis
Schistosomiasis remains one of the most prevalent parasitic diseases in the world, found
endemic in 76 countries and is a public health concern in the developing world [8]. Schistoso‐
Human Helminthiasis124
miasis is a chronic disease, poorly recognized at early stages and if untreated the disease
debilitates men and women during their most reproductive years. The disease is typically
common in areas of the economically disadvantaged people living in areas that have no access
to proper sanitation and good water supply systems. The high‐risk groups for schistosomiasis
are school age children, adolescents, reproductive women and also those whose occupations
involve contact with water, for example fishermen, farmers, irrigation workers and women in
their domestic tasks [8]. It is estimated that about 652 million people are at risk of infection
from the five human schistosome species (S. haematobium, S. mansoni, S. japonicum, S. interca‐
latum and S. mekongi) and that 193 million are infected of which 85% are on the African
continent [8]. Children between 5 and 15 years of age are the high‐risk group and suffer most
from morbidity due to high intensities of infection [9]. Though schistosomiasis has been
intensively investigated over the past half a century, alone or in combination with other
infectious diseases, a lot needs to be understood. Figure 3 gives a detailed analysis of the effects
of infection, the clinical evolution and the resultant severe diseases resolution and manifesta‐
tions. Progression to disease severity is compounded by many other conditions that include
the host genetics, coinfections by other parasites, intensity and duration of infection. However,
other conditions such as malnutritional status of the host that is common in resource‐limited
areas may also aggravate the infections to severe diseases condition.
Figure 2. A general life cycle of schistosome species [7]. The life cycle shows the different shell morphology of the inter‐
mediate host and the morphological appearance of the ova that is important for diagnosis.
The number of individuals with hydronephrosis due to S. haematobium infection has been
estimated to be close to 20 million, while about 70 million mainly school–age children suffer
from hematuria due to their water contact activities [8]. Indirect measurement of morbidity is
important in children, ranging from malnutrition, anemia, growth retardation, irritability and
cognitive impairment that result in poor performance in school. Sick children are often absent
from school, leading to loss in school performance and participation. Chronic irreversible
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sequelae, such as liver fibrosis, urinary tract obstruction and bladder cancer, become apparent
in schistosomiasis in adult age as a result of heavy infection that occurs during childhood. This
underscores the importance of repeated chemotherapy at regular intervals of young children
living in endemic areas in order to prevent development of irreversible sequelae in adulthood.
Genital schistosomiasis is also common in both males and females in endemic areas. Female
genital schistosomiasis (FGS) described as the presence of schistosome eggs on the upper or
lower part of the reproductive tract has been demonstrated in up to 75% of females living in
schistosomiasis endemic communities (Figure 4A and B) in Africa [10–12]. Reproductive
complications due to FGS include low birthweight, abortions, ectopic pregnancies, primary
and secondary infertility [13–16]. In African cultures, infertility in married couples is often
blamed on women. This leads to rejection by husbands, family and kinship group. The society
may not accept women who do not get pregnant [16]. It is also hypothesized that FGS facilitates
transmission of HIV [12, 17]. The far‐reaching consequences of schistosomiasis infection also
include reduced national economic growth and persistent poverty. However, treatment using
a single dose is now available, effective and safe to be taken by uninfected children or pregnant
mothers and, can easily be incorporated into regular field activities [18]. Any initiative to
control schistosomiasis will not only contribute towards morbidity reduction but also to the
control of HIV transmission, improvement of school health and performance of children,
national economic growth and poverty alleviation.
Figure 3. Indicating the contributing factors that drive one parasitic infection to clinical evolution and ultimately lead‐
ing to severe diseases.
2.2. Soil-transmitted helminthiasis
Soil‐transmitted helminthiases are nematodes transmitted from the soil to humans. These
include hookworms (Ancylostoms), round worms (Ascaris lumbricoides) and whip worms
(Trichuris trichiura). Like schistosomiasis, soil transmitted helminthes (STHs) are widely
distributed in economically disadvantaged communities who do not have sanitary facilities
[19]. The burden of the disease associated with STHs is enormous. Over two billion people are
infected worldwide and 135,000 people die annually from STHs infection [2, 19]. Again like
schistosomiasis, the most susceptible groups are primary and preschool‐aged children (5–15
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years). About 400 million school age children worldwide are infected with STHs [3]. Hook‐
worm infection is picked at the age of two years when children are frequently left to play on
contaminated soil and infection increases with age, age range (5–15 years) being the most high‐
risk group [19, 20]. Hookworm infection causes iron‐deficient anemia [21]. The intestinal stage
hookworms feed on blood and cause further hemorrhage when they stop feeding because they
release anticoagulant compounds. A single adult hookworm is estimated to cause a daily blood
loss into the gut of from 0.03 to 0.15 ml [21, 22]. Intestinal stage hookworms change position
every 4–6 h as they seek new sites for blood meal [23]. This mode of feeding is a major cause
of morbidity in young children and pregnant women who have high demand of iron or are
malnourished. Other effects of hookworm infection include itchy rash, cough, fever, bloody
sputum, and loss of appetite, nausea, vomiting, diarrhea, abdominal discomfort, paleness,
fatigue and blood in the stool [21].
Figure 4. Illustration of the female (A) and male (B) genital schistosomiasis affected areas. The affected areas may facil‐
itate easy transmission of HIV besides causing other reproductive complication leading to infertility.
Ascaris lumbricoides infection causes diarrhea, intestinal obstruction, reduced food intake,
abdominal pains, impaired fat digestion and Vitamin A absorption (leading to nutritional
deficiency). Infected children contaminate the soil by their indiscriminate defecation. Infection
causes reduced appetite leading to malnutrition, which in turn result in reduced host immune
resistance to other infections. Other effects include vomiting, jaundice, disturbed sleep, dry
skin and pneumonitis during larval passage in lungs. Trichuris trichiura (whipworm) cause
blood loss in the form of hemorrhage associated with trichuriasis dysentery syndrome or rectal
prolapse [22]. More commonly blood loss is believed to be part of an exudation from the
damaged epithelium and is proportional to parasite burden. Other effects of whipworm
infection include: diarrhea and pain in the right lower abdomen, anemia secondary to blood
loss and impaired learning (cognitive) ability [23]. Transmission of Ascaris lumbricoides and
Trichuris trichiura is through oral fecal route by ingestion of infective eggs. Children who are
most frequently exposed to contaminated soils are mostly infected than adults.
The conditions that support transmission of STH are similar to those favoring transmission of
schistosomiasis (poor sanitation, contamination of the environment with human excreta,
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poverty leading to lack of protective clothing and safe water supply). These conditions could
create an overlap of epidemiological distribution of schistosomiasis and STHs in some regions.
There is a high risk of morbidity exacerbation due to mixed infection from schistosomes and
STHs. At least 50% of severely ill people due to worm infestation are school age children [19,
24], and infection from STHs and schistosomiasis represent more than 40% of the disease
burden due to all tropical diseases, excluding malaria [25]. But these diseases are treatable. The
public health significance of schistosomiasis and STH has triggered response from WHO,
which in the 54.19th WHA 2001, demanded that all member state endemic to these NTDs
should provide regular mass treatment to primary school children at risk of morbidity due to
schistosomiasis and STH, with praziquantel and albendazole. There is a major shift in the
policy for the control of Preventative Chemotherapeutic Treatment of NTDs to that of control/
elimination [3].
2.3. Diagnosis
The standard diagnosis for schistosomiasis is detection of viable eggs in urine (S. haematobi‐
um), feces (S. japonicum, S. mansoni), or tissue biopsies. Currently, the presence of infecting
schistosomes cannot be ruled out definitively if no ova are detected in urine or feces, because
of the low sensitivity of the standard urine and fecal examinations [26]. Molecular techniques
to detect schistosome DNA in fecal specimens have greater sensitivity than microscopy, but
the techniques still suffer from sampling limitations because of the irregular distribution of
eggs in the excreta. Schistosome DNA detection in serum or urine is being evaluated [27].
Serological assays have proven useful for diagnosis as the techniques detect schistosome-
antigen–specific antibodies in symptomatic individuals. However, for individuals in endemic
areas for schistosomiasis, the serology is unable to discriminate between active infection and
past exposure. The main challenge of the serological assays is the inability to distinguish
between past and current active infection. However, a negative test can rule out infection in
endemic population, while another drawback is the test positivity over prolonged periods after
therapy making the tests unreliable for post-treatment follow-up [27]. Better diagnostic tests
for schistosomiasis are still needed for both in the field and in the clinic and new technologies
are being studied. Advances for drug development is also essential for diseases elimination
programs and vaccine assessment in which infection follow-up post-treatment must be
accurately monitored over time. Currently, there is a lack of true gold standard for quantitative
correlations to the actual worm burden [26]. An important public health aspect of monitoring
control and elimination programs would be detection of schistosome infections in the snail
host. Snail xenodiagnosis would enable the identification of environmental contamination
especially during the control and elimination programs by the use of snails located at selected
sentinel sites or assessing wild snails at common water contact sites [27]. The snail infections
are usually detected by inducing cercarial shedding, while prepatent infections can be
identified using histological examination of snail tissues and molecular parasitological
techniques such as polymerase chain reaction (PCR) or loop-mediated isothermal amplifica-
tion assays [28].
Human Helminthiasis128
2.4. Global control of helminthiasis
2.4.1. Vector control
The three major species of schistosomes that infect humans, S. mansoni, S. haematobium and
S. japonicum, are transmitted by specific genera of snails; Biomphalaria spp., Bulinus spp. and
Oncomelania spp., respectively. Vector control has most commonly been done through the use
of chemical molluscicides such as niclosamide [29]. The chemicals that kill snails are nonspe‐
cific and are also toxic for other aquatic life such as fish. Fish toxicity and yellowing of treated
water by niclosamide decrease the acceptability of mollusciciding by the communities [30].
The chemicals are expensive, while they can rapidly be washed down streams following rains
or diluted to nontoxic concentrations in larger water bodies, thereby demanding frequent
reapplication. Furthermore, training for personnel who apply molluscicides is required who
would understand the environmental conditions such as water hardness and temperature.
Indigenous plant extracts are an attractive alternative to chemicals for killing snails. These have
low costs due to local availability and the extracts are less toxic to other forms of aquatic life
[31]. The plant Phytolacca dodecandra has received some attention but has not been effectively
employed for schistosomiasis control. The intervention requires community involvement that
is dependent on participation rates that is affected by perceived importance of the intervention,
the ability to observe impact or personal benefits and the degree of input the population has
in designing the intervention [32]. Biological control is another approach to reducing snail
populations and impacting transmission of schistosomiasis. Prawns and crawfish can be used
to reduce snail populations, for example, M. vollenhovenii and Procambarus clarkii are voracious
consumers of snails. Certain species of fish are also predators for the snails that transmit
schistosomiasis. Cichlid populations are molluscivores that preferentially feed on Bulinus
spp. compared to snails with thicker shells [33]. Other attempts to alter snail populations
include environmental alterations such as removal of vegetation on which they feed, lining
canals with cement or draining water bodies where they live [34]. Attempts to directly remove
snails that included financial incentives for numbers of snails collected have been employed
but with increased infection risk to persons doing the work [35]. The applicability and efficacy
of this method in African settings is not appropriate. While in areas of high schistosomiasis
transmission, it has been reported that the number of infected snails is usually low, suggesting
that only a few infected snails maintain the life cycle [36]. Snails that are nonhosts for human
schistosomiasis and compete with or predate on intermediate host snails can be used for
control. Introduction of ampullarid (e.g., Marisa cornuarietis) or thiarid (e.g., Melanoides
tuberculata) snails in endemic areas in the Caribbean region was reported to successfully
displace populations of Biomphalaria spp. leading to reduction and interruption of S. mansoni
of transmission [37].
2.4.2. Health education
Health education is an important component of effective schistosomiasis prevention and
control. Developing health education programs requires that the design, administration and
outcomes be adapted to different socioeconomic and cultural settings [38]. Several studies have
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shown that the individual's behavioral changes facilitating disease prevention and control.
Behavior cannot be changed simply with the acquisition of knowledge that can be obtained
from health education [39]. Health education programs end up not successful when the
socioeconomic and cultural context of communities is not considered. Individuals and
communities have to be considered in full their environment and education when developing
programs for the control of diseases in an area. The success of programs in reducing high‐risk
behavior and promoting health‐enhancing behavior depends to a considerable degree on
whether the life cycle and other biomedical concepts and information are presented in an
appropriate, emotional, social, economic and cultural context of target populations. Consid‐
eration should be taken when people do not have the means for changing their behavior, for
example, inadequate health services, no access to proper sanitation and clean water supply,
unavailability of antihelminthic medications and unaffordability of modern treatment.
Observations were made in a longitudinal study conducted in Zimbabwe over 33 months in
which parasitology follow‐up examination and treatment was done every 6 months for the
first year, then a break for almost 24 months. The reinfection was observed to take place in such
an endemic setting rising to almost half the levels before treatment (Figures 5A–D). However,
after a long break of 24 months, the prevalence was seen to rise to almost pretreatment levels,
even though infection intensity was drastically reduced.
Figure 5. Showing a typical infection re‐infection longitudinal study conducted in Zimbabwe at 6 monthly observa‐
tions in the first year and then another examination after 24 months. Panel A: A typical age prevalence/egg intensity
curve in a community before treatment. Showing a peak within the 10–14‐year‐old age group. Panel B: S. haematobium;
Panel C: S. mansoni and Panel D: Soil‐transmitted helminths; infection prevalence and intensity of infection with fol‐
low‐up time point. Regular treatment was observed to be effective in prevention of heavy infections.
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2.4.3. Vaccines
Despite several years of mass antiparasitic drug therapy programs and other control measures,
helminthiasis still continues to exist. The discovery of a vaccine still remains a pipe dream for
the control of human helminthiasis. A vaccine would contribute to the reduction of schistoso‐
miasis morbidity through immune modulation leading to a decrease in parasite load and
reduced egg production. A lot of research has been done with a view of controlling and
preventing schistosomiasis. Researchers have focused on vaccines, host genetic predisposition,
coinfections, autoimmunity and improved diagnostics for surveillance.
Several candidate human schistosomiasis vaccines are in different stages of preclinical and
clinical development. The most eligible candidates are egg antigens and the schistosomula
tegument membrane antigens (Sm 23, SmTSP‐2 and Sm29) [40] of S. haematobium and S.
mansoni. Two recombinant S. mansoni vaccines; Sm‐TSP‐2 and Sm‐14 are being tested, while
Smp80 (calpain) is undergoing testing in nonhuman primates [40]. The Sh28GST, also known
as Bilhvax is in advanced clinical development for S. haematobium infection. These vaccines
were selected on the basis of their protective immunity in preclinical challenge models, through
human immune‐epidemiological studies or both [41]. The vaccine candidate development and
evaluations are being advanced through collaboration of academic research institutions,
nonprofit vaccine product development partnerships, biotechnology companies, and devel‐
oping country vaccine manufacturers. The success in developing promising vaccine candidates
has been possible from screening schistosome OMICs databases using DNA microarray
profiling, proteomics, glycomics and immunomics [42] and the application of RNA interfer‐
ence (RNAi) technology that has allowed investigators to ascribe specific functions to the
parasite molecules and the role in parasite survival [43]. A potential strategy that could
accelerate the achievement of an effective vaccine would be the association of different
recombinant antigens that previously resulted in partial protection or the use of pools of
antigens known as multivalent or multiepitope vaccines [42].
The vaccine development strategies are bedeviled with many biological bottlenecks such as
the lack of reliable surrogates of protection in humans; immune interactions in coinfections
with other diseases in endemic areas; the potential risk of IgE responses to antigens in endemic
populations; and paucity of appropriate vaccine efficacy studies in nonhuman primate models.
Research is also needed on the role of modern adjuvants targeting specific parts of the innate
immune system to tailor a potent and protective immune response for lead schistosome vaccine
candidates with the long‐term aim to achieve curative worm reduction [44].
3. Immunology
Immune responses during schistosomiasis can be considered in terms of three broad aspects
of immunopathogenesis, resistance to reinfection and immunodiagnostics. The develop‐
ment and establishment of chronic infection is impacted by the presence of chronic antigenic
exposure as illustrated in Figure 2 and summarized in Figure 3. The immunological regula‐
tion associated with the morbidity of schistosomiasis has been studied without completely
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understanding the impact [45, 46] of the immunological components involved that contrib‐
ute to failure to design successful vaccines. However, the immune mechanisms related to
resistance to reinfection and in response to candidate parasite antigens are not well defined.
Adult worms are known to be refractory to immune attack; while immature and developing
worms, skin‐stage and lung‐stage schistosomulae are the probable targets of protective im‐
munity [46, 47] that are safe from drug effects. Whether a protective resistance to reinfection
exists is still not well characterized and understood [47, 48], but evidence suggests that such
resistance may develop rather slowly [46, 47]. The induction of protective immunity has
been shown through immunization of various experimental hosts with irradiated cercariae
to work for a short period of time. Data from endemic populations suggest that age‐associ‐
ated decreases in infection result from the development of antiparasite immunity, rather
than reduced contact with water [24]. Although the responsible antigens and host immune
responses are not fully defined, resistance to reinfection is believed to be associated with IgE
antibodies against worm antigens, with low concentrations of IgG4 antibodies to worm anti‐
gens and high blood eosinophilia. Resistance to reinfection is partial, which means that pro‐
tective sterile immunity either does not develop or is rare. Treatment of schistosomiasis
increases common correlates of resistance: eosinophilia, parasite‐specific IgE and interleukin
5 production in response to worm antigens, while repeated treatment to prevent reinfec‐
tions can lead to longer intervals before reinfection, even accounting for similar exposure
patterns in highly exposed participants [48].
3.1. Coinfections
Neglected tropical diseases are found in areas that have conducive environmental conditions.
Schistosomiasis and soil‐transmitted helminthiasis often occur alongside each other and with
other tropical infectious diseases and with a wide range of coinfecting organisms. In addition
to the direct morbidities, schistosomiasis can affect immunological and physiological respons‐
es of the host and the coinfecting pathogens. Thus, better control of schistosomiasis could
provide adjunctive benefits towards other coinfecting organisms in such areas. The most
studied and compelling example is the effect of schistosomiasis on susceptibility to HIV
infection. Among women with female genital schistosomiasis, the inflammation of the genital
epithelial tissue can lead to a compromised physical barrier to exposure to HIV through sexual
activity. In population‐based studies, female genital schistosomiasis has been associated with
a three to four times increased risk of HIV infection [10–12, 16, 17, 49].
Schistosomiasis alters immune responses directed towards coinfecting pathogens, allergens
or vaccines. The immunoregulatory responses during schistosome infection could downre‐
gulate T‐helper type‐1 immune response associated with the control of viral or protozoan
infections or interfere with immunization generally made available to children living in af‐
fected tropical areas. In one of many studies of schistosomiasis and malaria coinfections it
seems to indicate that schistosomiasis modulates malaria; however, studies have yielded con‐
flicting results [50–54]. In some cases, malaria prevalence, anemia and pathological effects are
higher in children with schistosomiasis than in children without schistosomiasis, whereas
antimalarial immune responses are diminished [51]. However, other studies report no protec‐
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tive effect of schistosome infection on malaria that can be accompanied by increased immune
responses [53, 54]. Schistosome and malaria‐related antigens can cross react to some extent,
further complicating the situation. However, within the host there is need for a delicate but
subtle interplay between pro‐ and anti‐inflammatory cytokines that play a major controlling
effector role on the antibody production and the cell‐mediated antibody dependent cytotox‐
icity (Figure 6A and B).
Figure 6. Plate A, Pro‐ and anti‐inflammatory cytokines involved in a delicate balances that play an important role in
down regulating deleterious effector response to helminthiasis invasion. Plate B, Illustrating the key T‐helper subsets
that are important in helminthiasis infections, control and regulation to avoid development of immunopathology.
3.2. Host immunogenetics
The development of genetic epidemiology methods using recent human genetic mapping
information has led to major advances in the identification of host genes in human schistoso‐
miasis and other infections [55]. Determining the role of host genetics in schistosomiasis is
complicated by the numerous parasite and environmental factors involved in transmission.
Two immunological and pathological phenotypes have been studied so far as schistosomiasis
infection levels on the host‐parasite as consequences measured by the fecal egg counts and the
severe hepatic fibrosis assessed by ultrasound examination. The first study was performed on
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Brazilian pedigrees and provided strong evidence for a major gene controlling infection
levels by S. mansoni denoted as SM1, which was mapped to chromosome 5q31-q33 [55]. This
region contains several candidate genes involved in the regulation of the Th1/Th2 responses.
The direct role of cytokine polymorphisms located within these genes further elucidation.
Another study conducted in Sudan showed the presence of a major gene influencing the
development of severe hepatic fibrosis during S. mansoni infection denoted as SM2. This gene
is located on chromosome 6q22-q23 and is closely linked to the IFN-gamma receptor 1 gene
encoding the receptor of the strongly antifibrogenic cytokine interferon-gamma. There is also
evidence for the genetic control of pathology due to S. mansoni, where the linkage is reported
on a region containing the gene for the interferon-gamma receptor 1 subunit. Numerous
association studies have also provided evidence for major histocompatibility complex control
of pathology in schistosomiasis through cytokine polymorphisms [55–57]. Host immunoge-
netics is important in driving the host immune effector mechanisms such that cytokine
polymorphisms may be crucial in the expression of resistance or susceptibility to a host of
infections [57, 58]. Any impact on the underlying immune genetics (Figure 7), would impact
the cytokines expression and antibody production [58].
Figure 7. Showing the link of the antigen presentation to the T-helper cell subsets including T-regulatory cells. The T-
helper cells produce a barrage of cytokines that selectively influence B cells at gene level to class switch antibody pro-
duction leading to the synthesis of either protective or blocking antibodies [58].
4. Mass drug administration (MDA)
Mass drug administrations (MDA) in affected populations or communities form the basis of
current schistosomiasis and soil-transmitted helminthiasis (STH) control and/or management.
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The MDAs can follow one or more of the following approaches; house‐to‐house administra‐
tions (i.e., mobile teams), booth distribution (i.e., fixed teams), administering drugs in special
population groups (e.g., school age children, etc.) and/or areas of community gatherings (e.g.,
marketplaces, stations, etc.) [2]. Such chemotherapeutic prevention and management strat‐
egies of infectious diseases in endemic areas have some significant shortcomings, chief among
them being re‐infections [59, 60], due to untreated human and animal reservoirs. Prophylactic
measures in these areas are difficult as that would mean people will have to take the medicines
frequently for life, thus exposing them to potential life‐threatening adverse drug events and
development of drug resistance. In endemic areas during a five‐year round of annual mass
treatment of school going age children, before and post‐treatment checks revealed that re‐
infection always takes place (Figure 5). Reinfections were most common in cases where MDA
was not accompanied with adequate environmental and health promotion/education inter‐
ventions. Successful MDA in endemic areas has to be conducted in all age groups. For better
coverage, the World Health Organization recommends the utilization of all available medicine
distribution channels especially in countries with high levels of infections [60–64].
Repeated MDAs have helped some countries to significantly reduce the disease burden. An
example is the 84% reduction of baseline levels of schistosomiasis in a moderately highly
endemic region of the northeast of Sierra Leone, with MDA interventions repeated yearly over
three years [61]. Communities in Zanzibar, Tanzania also recorded significant reductions in
infections levels of soil‐transmitted helminthiasis (90–98%) and scabies (68–98%) as additional
benefits associated with the annual mass drug administration of ivermectin and albendazole
for lymphatic filariasis. Modeling done by Anderson et al. [62] noted that it was possible to
even eliminate S. mansoni by WHO’s MDA guidelines at least in areas with lower transmission
levels if high coverage is attained and maintained beyond above 75% coverage [64]. The noted
disease burden reductions also have positive impact on morbidities and comorbidities like
anemia, malaria and HIV [49, 64].
Despite significant contributions, great optimism and positive outlook; MDA may not lead to
total elimination on its own [63]. There is a great need for critical assessments of all MDAs for
more positive effects to be realized. Significant community effectiveness of MDA programs
stand challenged by issues around; very low coverage (<75%) as about a third of those that
really require treatment and/or chemoprophylaxis are receiving it [64, 65]; the utilization of
volunteers and/or underpaid workers to distribute or administer medicines; overly relying on
fragile healthcare systems in marginalized communities or countries; lack of health and/or
pharmacoeconomic evaluations; sustainability questions associated with all chemo‐prophy‐
laxis interventions; belief systems, socioeconomic status and general community acceptance;
lack of evidence of wider safety and effectiveness of medicines involved in different commun‐
ities and fears of exerting unnecessary selection pressure, thus promoting drug resistance [63–
65]. Despite the noted negative concerns, MDA remain popular in the prevention and/or
management of schistosomiasis and soil transmitted helminthiasis. As highlighted above
WHO suggests ways by which wider coverage can be attained like utilization of all available
medicine distribution channels. Also because in almost all affected and/or poor countries
developmental partners and international pharmaceutical companies finance the MDAs, as
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such the programs remain cost‐effective at least from a governmental perspective of pharma‐
coeconomic evaluations. Issues to do with community acceptance may be addressed by
adequate promotional and/or educational programs to clearly explain the aims and objectives
of each MDA intervention. Critical evaluation of each MDA intervention on issues to do with
safety, drug effectiveness, cost‐effectiveness/benefit, sustainability and political will positively
feed into the subsequent interventions.
4.1. Helminthiasis management
For schistosomiasis, WHO recommends praziquantel with doses of 40–60 mg/kg body weight
in one and/or 2–3 divided dose(s). Praziquantel is effective against all five important species
of schistosomes, that is, Schistosoma mansoni, S. haematobium, S. japonicum, S. intercalatum and
S. mekongi. Praziquantel ‘the first antihelminthic drug to fulfill the World Health Organization’s
requirements for population‐based chemotherapy of a broad range of parasitic infections’ is
also effective against clonorchiasis, opisthorchiasis, paragonimiasis, taeniasis and intestinal
trematodiases. Other drugs with recognizable effectiveness against schistosomiasis are
metrifonate and oxamniquine. Metrifonate is an organophosphate cholinesterase inhibitor
thus it has significant safety issues. Oxamniquine has a complicated manufacturing process,
which drives manufacturing cost up [65]. Thus, oxamniquine costs way more than
praziquantel, making it unfavorable for wider mass usage. Praziquantel was demonstrated to
be way more effective as compared to oxamniquine, when used in a controlled trial cure rate
for praziquantel was high (96.1%) while that of oxamniquine was low (42.4%) [66].
Praziquantel remains the first and only choice in all cases of schistosomiasis owing to its low
cost, high efficacy, low toxicity and ease of administration. The acceptable attribute is mostly
single oral doses that enhances compliance.
The mechanism of action of praziquantel is thought to involve the increased permeability to
Ca2+ ions leading to uncontrollable contractions, paralysis and death of the worm. It is also
suggested that it leads to vacuolation and blebbing of worm tegumental and subtegumental
structures in adults but not juveniles worms [67, 68]. This leads to the exposure of surface
antigens to host immune system thus Facilitating immune recognition and clearance of the
worm [67]. The drug effect may be explained due to relative differences in sensitivities
observed in some settings between adult and juvenile worms [67]. Praziquantel is well
absorbed orally (80%), is subjected to first pass effect, metabolized by the liver and excreted
via the kidneys [19]. Microsomal enzymes inducers like rifampicin interfere negatively with
praziquantel efficacy as they lead to lower than minimum effective concentration of prazi‐
quantel in the blood. On the other hand, CYP450 inhibitors like cimetidine, ketoconazole, grape
juice, etc. may lead to higher than normal blood levels. It is contraindicated in patients with
history of epilepsy and those hypersensitive to it. Operation of machinery or driving by
individual after intake is not recommended. There is no evidence linking praziquantel to
mutagenesis or harmful effects to fetuses. But as a general rule drugs are best avoided in the
first trimester and used during the rest of pregnancy when benefits outweighs risks [19]. The
usual mild side effects of praziquantel which generally do not require treatment are malaise,
headache, dizziness, abdominal discomfort with or without nausea and/or vomiting, fever and
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urticarial. Some of these side effects may be altogether the effects of schistosomiasis. These and
other side effects may be worse in patients with high worm burden. Resistance to praziquantel
by schistosomes has not been reported as yet, as there are no substantiated clinical findings.
Reports of resistance are usually misrepresentations of issues like noncompliance or very
transient biological phenomena or effects [67, 68].
4.1.1. Management of soil‐transmitted helminthiasis
In the management of STH, the WHO recommends any of the following drugs: albendazole
(dose of 400 mg); mebendazole (dose of 500 mg); levamisole (dose of 2.5 mgkg−1) and pyrantel
(dose of 10 mgkg−1). These drugs are effective against many helminthic infections, for example
ascariasis, hookworms, lymphatic filariasis, trichuriasis, strongyloidiasis, zoonotic ancylosto‐
miasis, enterobiasis, among others. Benzimidazoles (i.e., albendazole and mebendazole) are
the mostly commonly used [58, 65] in the management of STHs owing to their efficacy, wider
spectrum, safety and availability. Benzimidazoles are thought work through inhibiting tubulin
polymerisation. Absorption of albendazole is usually very low and the absorbed is subjected
to significant first pass effect by the liver. Mebendazole is absorbed almost fourfold better than
albendazole, but the rest are similar. May cause bone marrow suppression if taken for a
considerable long period as in hydatid disease management were the patient takes three 28
day cycles with 14 day breaks of albendazole. Benzimidazoles are best avoided in pregnancy
especially during the first trimester unless good clinical advice benefits outweigh risks [19].
Without having the pharmacokinetic properties changed, praziquantel increases plasma
concentration and area under the curve of albendazole sulfoxide (the most active metabolite)
by about 50% in healthy subjects. This might be beneficial in coadministration as in MDAs,
but also may lead to more side/adverse effects. Side/adverse effects of albendazole depending
on the duration of therapy may include, abdominal pain, nausea and vomiting, fever, elevated
hepatic enzymes, dizziness, headache, meningeal signs, raised intracranial pressure and
vertigo hypersensitivity
Benzimidazoles are active against Ascaris lumbricoides, Enterobius vermicularis, Necator ameri‐
canus, Ancylostoma duodenale, Trichuriasis, Strongyloidiasis, Trichinella spiralis, neurocysticer‐
cosis, cystic hydatid disease and microspiridiosis. Resistance to albendazole though rare occurs
through alteration of the target site. The other drugs highlighted above are better reserved for
drug‐resistant worms. Levamisole is now in most guidelines reserved for veterinary use. Also,
pyrantel has an inferior effective profile as compared to benzimidazoles. For long‐term
solutions, there is a need to combine MDA with various other strategies like improving the
quality of the water supply, sanitation and hygiene, education and health promotion and
intensify the search for vaccine development. Levamisole and pyrantel are not widely used,
but since they are not in the same class as albendazole and mebendazole, they are usually
reserved for drug‐resistant forms of STHs. Thus, MDAs with praziquantel and a benzimida‐
zole have a wide spectrum covering against important helminths. Coadministration has
additional benefits that can be realized if regular MDAs are done in affected communities.
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4.1.2. Safety of combining praziquantel and benzimidazoles
High safety profile has been observed, in a safety study of praziquantel – albendazole com‐
bined treatment of hydatidosis, which require a way more prolonged duration than schisto‐
somiasis and/or STHs [69]. The mild side effects noted were not so different from when
monotherapies were used and were transient, disappearing when treatment was withdrawn
[69]. There may be need for more evaluations of the severity of side and/or adverse‐effects
versus worm burden, when worms are localized in the central nervous system and/or in eyes.
4.2. New chemotherapeutic avenues
Mathematical models suggest significant drug resistance by the helminths to current therapies
in the new future [70], the need for new, safer and more effective drugs is apparent. It has been
demonstrated that the use of praziquantel and other drugs may enhance the antischistosomal
activity. An example of such drugs is lovastatin [65] (a hypolipidemic agent). Benzodiazepines
such as clonazepam are known to have the ability to paralyze adult schistosomes (both males
and females) and interfere with egg release [65]. Other promising molecules with antischisto‐
somal activities are the artemisinins and related 1,2,4‐trioxolanes [68]. Praziquantel and
artemisinin derivatives combined offers better protection [69] and/or cure rates. Though not
100% effective, MDAs based on WHO guidelines are very important in the fight against many
parasitic neglected tropical diseases like schistosomiasis and soil transmitted helminthiasis.
MDAs has actually more benefits due to the wider spectrum of both praziquantel and
albendazole/mebendazole, as the administration will cover other parasitic infections within
targeted communities. Effectiveness is significantly improved if chemoprophylaxis is done
together with education and promotion of hygiene and the use of safe water. While prazi‐
quantel and albendazole/mebendazole are very effective there is still need to develop new
better pharmaceuticals and pursue other avenues like vaccines.
4.3. Schistosomiasis control and elimination: research priorities and capacity building needs
The WHO/TDR Special Program for Research and Training in Tropical Diseases convened
diseases reference groups to examine and set research priorities for the neglected tropical
diseases. The following research priorities were made: (i) to optimize existing intervention
tools so as to maximize impact and sustainability, (ii) to develop novel control tools that will
improve impact and sustainability, (iii) to improve diagnostic tests with good sensitivity,
specificity, multiplex capacity, and ability to measure infection intensity, and detect drug
resistance; especially useful at the current preventive treatment control initiative in which
reinfection would be very low. There is also need (iv) to standardize and validate methodol‐
ogies and cost effective protocols for diagnosis in monitoring and evaluation settings, (v) to
develop delivery strategies of multiple interventions to maximize sustainability of control
program and integrated neglected tropical diseases control. Recommendation also included
the need to develop strategies to increase awareness of ill‐health processes, community
participation, ownership and empowerment, as well as equity in access to preventive chemo‐
therapeutic control interventions. The application of epidemiological models is required to
help monitoring of intervention efficacy including drug resistance tracing. Further to develop
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new tools for parasite functional genomics in key species, this is believed to assist in vaccine
development. A comprehensive research agenda need to be developed from basic sciences to
emphasize implementation research and to ensure that control program could be implemented
and evaluated based on rigorous scientific evidence. New tools, policies and strategies would
lead to strengthened control programs that aim at disease elimination or eradication, where
feasible.
4.4. Progress of schistosomiasis preventive chemotherapy in the African region: challenges
and research needs
The African region has the highest burden of schistosomiasis, with 4 intermediate host species,
endemic in 43 countries. According to WHO statistics at least 220 million people may have
schistosomiasis infections. Ten sub‐Saharan countries account for more than 70% of the global
number of people requiring preventive chemotherapy for schistosomiasis. Prevalence of
infection and morbidity are high in school‐age children, but high prevalence has also been
documented in children less than 5 years of age [71, 72]. The African region has adopted and
recommends a comprehensive control strategy for schistosomiasis that includes preventive
chemotherapy, health education, access clean water, sanitation and environmental control.
These strategies, if implemented vigorously, would lead to the reduction of morbidity and
possibly interruption of transmission. However treatment coverage is low in the region and
many countries are not yet mapped. Scaling up to reach at least 75% of children is still a
challenge because of access to praziquantel. Treatment of pre‐school children is also limited
by the lack of a pediatric formulation [52].
Research priorities for schistosomiasis control and elimination in endemic region include, better
understanding of the epidemiology and surveillance of infections, implementation research,
environmental and social ecology, better use of data and modeling and the basic biology of
transmission and snail dynamics [73]. These priorities can only be met through widespread
capacity strengthening and collaborative partnerships, transparent interactions between
researchers and disease control program managers, learning from areas that have successfully
controlled and have experience in research and control of schistosomiasis, for example, China,
including intersectorial collaboration and technology transfer and political commitment and
funding for disease control and research in each affected country. Conduct of the required
research should also be done so as to increase capacity for advanced research as well as to
improve disease control. Capacity strengthening should provide personnel able to address gaps
from the laboratory to the field, and with skills to properly evaluate interventions, model likely
progression and scenarios and quantify impacts of the control program. For schistosomiasis
control and elimination, it will be important to rebuild capacity for malacology, which was not
stressed when preventive chemotherapy was the main operational component. Other aspects
to be strengthened are drug efficacy monitoring, and pharmacovigilance.
4.5. Monitoring and evaluation towards the elimination of schistosomiasis
Monitoring and evaluation (M&E) is a process that helps to improve performance and ach‐
ieve planned targets. The goal should be to improve current and future management of out‐
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puts, outcomes and impact. The results of M&E should help control programs, governments
and development partners assess the performance and progress towards schistosomiasis
control and elimination. These processes should also document past and current interven‐
tions, as well as for planning future activities. Monitoring should be incorporated and im‐
plemented from the planning stage of a program as a periodic and recurring task.
Documenting results, processes and experiences should steer decision‐making and learning
processes. Monitoring checks progress against plans. The data acquired through monitoring
is used for evaluation.
Evaluations should help to draw conclusions about efficiency, effectiveness, impact, relevance
and sustainability of the interventions. The process consolidates information and allows
program managers to learn from each other’s experiences, building on expertise and knowl‐
edge; generates reports that contribute to transparency and accountability of donated resour‐
ces. Evaluation may reveal errors and offers alternative ways for improvements. Evaluation
documentation provides means by which agencies consolidate and learn from their experien‐
ces making policy to guide control and monitoring activities. Evaluations also provide ways
to assess the success of the program and the relationship between implementers, decision
makers and beneficiaries. Evaluation results provide evidence for raising funds, influencing
policy and tracking the success of the program. The assessments of activities depend to a large
extent on the manner in which monitoring and evaluation is recommended. Assessment of
performance is necessary to select indicators that permit rating of the targeted outputs and
outcomes before the implementation of the project.
Parasitological indicators: This aspect using parasitology to determine number of people
screened for infection, number of people positive, number of people requiring preventive
chemotherapy, number of people treated and the positive numbers to be treated.
Malacological indicators: The indicators here show the number of areas that need survey, the
number of areas that are high transmission, the number of areas that need molluscicides/snail
control and the number of areas that have been treated/modified.
There should be indicators for other interventions such as health education, water supply and
sanitation. Evaluation should inform whether planned tasks are completed or on‐going.
Quality control and effectiveness of all interventions should be assured.
5. Concluding remarks: mass drug administration for the control of
helminthiasis
Tropical and subtropical areas have conducive environment for the flourishing of helmin‐
thiasis; these include appropriate temperature, wet and humid soils, abundant fresh flow‐
ing river waters and the human factor that continuously contaminates their environment
and maintains the life cycle of the parasites. Vaccines are still a long way to be developed
since we lack complete understanding of the host‐parasite relationship. Host‐parasite ef‐
fects have been observed those leading into severe pathology, in some instances, during the
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parasite colonization. The effects of helminthiasis are so diverse affecting the health of the
host resulting in poor cognitive in school children, affecting reproductive health in child‐
bearing age and reduced work output in economically engaged workforce. The current
control strategy is by removing the infection using preventive chemotherapy, ultimately an‐
ticipating cutting the life cycle of helminthiasis after several rounds of treatment using
mass drug administration. While controlling the life cycle by treatment, much effort should
be invested in health education to reduce contamination of the environment. The overall
control strategies required should include health education, water and sanitation develop‐
ment, selective chemotherapy, snail control and passive treatment of cases. The options for
consideration of water and sanitation development remain a major challenge since this is
grossly neglected in most developing areas that are resource limited. While additional en‐
vironmental and engineering measures for irrigation schemes particularly the small scale
irrigation currently being developed require incorporation of the helminthiasis control
strategy right from the onset of program development. Use of indigenous and locally avail‐
able resources in vector control should be included in health education and basic health
delivery services (e.g., plant molluscicide — Phytolacca dodecandra). This can be grown as
homestead or garden hedge whose berries can be crushed for local application at water
contact sites for the control of snail vectors. Concerted efforts from all partners in human
development need to be involved in the control of helminthiasis. Partnerships with other
sectors in the farming, irrigation, health education and mining is required for the common
goal to develop and improve human living standards in an effort to control helminthiasis
from all angles.
Finally, recommendations are made for comprehensive, integrated and through multi‐
disciplinary intervention strategies that include preventive chemotherapy, environmental
management, water conservancy, water supply and sanitation development in affected areas
and snail control using locally available resources. Such strategies should be evidence‐based
from research component incorporated in the control activities and use of the most up to date
technologies and tools in control. Collaboration would be a platform for capacity strengthen‐
ing, technology transfer and expertise for the elimination of schistosomiasis from Africa.
Above all there is need to obtain government political will for support and sustainability of
the programs.
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